FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117948975> ?p ?o ?g. }

• W2117948975 endingPage "1272" @default.
• W2117948975 startingPage "1265" @default.
• W2117948975 abstract "Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in a high percentage of medullary thyroid carcinomas (MTC). Analogous to somatostatin receptors, CCK-2 receptors might be viable targets for radionuclide scintigraphy and/or radionuclide therapy. Several CCK-2 receptor-binding radiopeptides have been developed, and some have been carried through into clinical studies. However, these studies are mostly limited and difficult to compare. The aim of this study was to evaluate the diagnostic and therapeutic potential of three promising CCK-2 receptor-binding radiopeptides in patients with MTC.(111)In-DOTA-(D: )Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH(2) ((111)In-DOTA-CCK), a CCK analogue, and the gastrin-based ligands (99m)Tc-N(4)-Gly-(D: )Glu-(Glu)(5)-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH(2) ((99m)Tc-demogastrin 2) and (111)In-DOTA-(D: )Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH(2) ((111)In-DOTA-MG11) were each administered to the same group of six patients. Planar images made at 3-5, 7 and 24 h p.i. were used for comparison of tumour visualisation and renal uptake.(99m)Tc-demogastrin 2 scintigraphy visualised all known lesions and new lesions in four of six patients. (111)In-DOTA-CCK and (111)In-DOTA-MG11 on the other hand missed several lesions; tumour uptake of these two radiopharmaceuticals was quite low. Comparison of retention of renal activity showed no major differences between the three radiopeptides.(99m)Tc-demogastrin 2 scintigraphy appeared most promising as a diagnostic tool in patients with MTC. Further studies are required to evaluate its value in patient management. Direct comparisons of the compounds studied strongly suggests that (111)In-DOTA-CCK and (111)In-DOTA-MG11 have less potential as imaging agents than (99m)Tc-demogastrin 2. These DOTA-linked compounds are considered unlikely to be useful for radionuclide therapy because of low tumour uptake." @default.
• W2117948975 created "2016-06-24" @default.
• W2117948975 creator A5006225939 @default.
• W2117948975 creator A5007539874 @default.
• W2117948975 creator A5007991478 @default.
• W2117948975 creator A5017297934 @default.
• W2117948975 creator A5023302477 @default.
• W2117948975 creator A5026949184 @default.
• W2117948975 creator A5029897786 @default.
• W2117948975 creator A5040369608 @default.
• W2117948975 creator A5063142468 @default.
• W2117948975 creator A5079838266 @default.
• W2117948975 creator A5082235979 @default.
• W2117948975 date "2009-03-06" @default.
• W2117948975 modified "2023-10-01" @default.
• W2117948975 title "Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma" @default.
• W2117948975 cites W1502206987 @default.
• W2117948975 cites W1975013384 @default.
• W2117948975 cites W2032525074 @default.
• W2117948975 cites W2057996834 @default.
• W2117948975 cites W2065361341 @default.
• W2117948975 cites W2075075102 @default.
• W2117948975 cites W2104660424 @default.
• W2117948975 cites W2119399289 @default.
• W2117948975 cites W2152588787 @default.
• W2117948975 cites W2156078646 @default.
• W2117948975 cites W4238166074 @default.
• W2117948975 cites W4376848539 @default.
• W2117948975 doi "https://doi.org/10.1007/s00259-009-1098-9" @default.
• W2117948975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2709231" @default.
• W2117948975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19266197" @default.
• W2117948975 hasPublicationYear "2009" @default.
• W2117948975 type Work @default.
• W2117948975 sameAs 2117948975 @default.
• W2117948975 citedByCount "73" @default.
• W2117948975 countsByYear W21179489752012 @default.
• W2117948975 countsByYear W21179489752013 @default.
• W2117948975 countsByYear W21179489752014 @default.
• W2117948975 countsByYear W21179489752015 @default.
• W2117948975 countsByYear W21179489752016 @default.
• W2117948975 countsByYear W21179489752017 @default.
• W2117948975 countsByYear W21179489752018 @default.
• W2117948975 countsByYear W21179489752019 @default.
• W2117948975 countsByYear W21179489752020 @default.
• W2117948975 countsByYear W21179489752021 @default.
• W2117948975 countsByYear W21179489752022 @default.
• W2117948975 countsByYear W21179489752023 @default.
• W2117948975 crossrefType "journal-article" @default.
• W2117948975 hasAuthorship W2117948975A5006225939 @default.
• W2117948975 hasAuthorship W2117948975A5007539874 @default.
• W2117948975 hasAuthorship W2117948975A5007991478 @default.
• W2117948975 hasAuthorship W2117948975A5017297934 @default.
• W2117948975 hasAuthorship W2117948975A5023302477 @default.
• W2117948975 hasAuthorship W2117948975A5026949184 @default.
• W2117948975 hasAuthorship W2117948975A5029897786 @default.
• W2117948975 hasAuthorship W2117948975A5040369608 @default.
• W2117948975 hasAuthorship W2117948975A5063142468 @default.
• W2117948975 hasAuthorship W2117948975A5079838266 @default.
• W2117948975 hasAuthorship W2117948975A5082235979 @default.
• W2117948975 hasBestOaLocation W21179489751 @default.
• W2117948975 hasConcept C126322002 @default.
• W2117948975 hasConcept C134018914 @default.
• W2117948975 hasConcept C170493617 @default.
• W2117948975 hasConcept C178790620 @default.
• W2117948975 hasConcept C185592680 @default.
• W2117948975 hasConcept C197404232 @default.
• W2117948975 hasConcept C2776297358 @default.
• W2117948975 hasConcept C2776667971 @default.
• W2117948975 hasConcept C2777593968 @default.
• W2117948975 hasConcept C2779902710 @default.
• W2117948975 hasConcept C2779931791 @default.
• W2117948975 hasConcept C2989005 @default.
• W2117948975 hasConcept C2993294228 @default.
• W2117948975 hasConcept C2993559085 @default.
• W2117948975 hasConcept C526584372 @default.
• W2117948975 hasConcept C71924100 @default.
• W2117948975 hasConceptScore W2117948975C126322002 @default.
• W2117948975 hasConceptScore W2117948975C134018914 @default.
• W2117948975 hasConceptScore W2117948975C170493617 @default.
• W2117948975 hasConceptScore W2117948975C178790620 @default.
• W2117948975 hasConceptScore W2117948975C185592680 @default.
• W2117948975 hasConceptScore W2117948975C197404232 @default.
• W2117948975 hasConceptScore W2117948975C2776297358 @default.
• W2117948975 hasConceptScore W2117948975C2776667971 @default.
• W2117948975 hasConceptScore W2117948975C2777593968 @default.
• W2117948975 hasConceptScore W2117948975C2779902710 @default.
• W2117948975 hasConceptScore W2117948975C2779931791 @default.
• W2117948975 hasConceptScore W2117948975C2989005 @default.
• W2117948975 hasConceptScore W2117948975C2993294228 @default.
• W2117948975 hasConceptScore W2117948975C2993559085 @default.
• W2117948975 hasConceptScore W2117948975C526584372 @default.
• W2117948975 hasConceptScore W2117948975C71924100 @default.
• W2117948975 hasIssue "8" @default.
• W2117948975 hasLocation W21179489751 @default.
• W2117948975 hasLocation W21179489752 @default.
• W2117948975 hasLocation W21179489753 @default.
• W2117948975 hasLocation W21179489754 @default.
• W2117948975 hasLocation W21179489755 @default.

• next